Impact of the Women's Health Initiative Trial Results on Hormone Replacement Therapy

Pharmacotherapy

Volumn 24, Issue 4, 2004, Pages 495-499

  Bestul, Megan B ^a   McCollum, Marianne ^a   Hansen, Laura B ^a   Saseen, Joseph J ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Box C238 ^*  (United States)

Author keywords

Hormone replacement therapy; HRT; Women's Health Initiative

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DECISION MAKING; DEMOGRAPHY; DRUG WITHDRAWAL; HEALTH STATUS; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; UTERUS;

AGED; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFORMATION DISSEMINATION; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; WOMEN'S HEALTH;

EID: 1842584818     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.5.495.33349     Document Type: Review

References (26)

1. North American Menopause Society. Menopause core curriculum study guide, 2nd ed. Cleveland, OH: North American Menopause Society, 2002.
2. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002;288:366-8.
3. Speroff L, Symons J, Kempfert N, Rowan J. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. Menopause 2000;7:383-90.
4. Notelovitz M, Cassel D, Hille D, et al. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2000;182:7-12.
5. McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med 1999;131:605-16.
6. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
7. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
8. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
9. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336: 1769-75.
10. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995;85:1128-32.
11. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
12. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of osteoporotic fractures research group. Ann Intern Med 1995;122:9-16.
13. Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990;113:95-103.
14. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998;128:705-12.
15. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.
16. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
17. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
18. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994;5:491-500.
19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-33.
20. National Institutes of Health. News release. NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk, lack of overall benefit. Available from http://www.nhlbi.nih.gov/new/press/02-07-09.htm. Accessed August 27, 2002.
21. Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative study. JAMA 2003;289:3241-2.
22. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
23. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
24. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
25. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635-45.
26. Steinberg EP. Improving the quality of care - can we practice what we preach? N Engl J Med 2003;348:2681-3.